TipRanks
Advertisement
Advertisement
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
PremiumThe FlyStructure Therapeutics reports ACCG-2671, aleniglipron trial results
19d ago
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results
Premium
Company Announcements
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results
19d ago
Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target
Premium
Ratings
Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target
2M ago
Buy Rating Reiterated on Structure Therapeutics as Obesity Pipeline Advances; $104 Price Target Maintained
PremiumRatingsBuy Rating Reiterated on Structure Therapeutics as Obesity Pipeline Advances; $104 Price Target Maintained
2M ago
Shareholders Approve Directors, Auditors at 2026 Meeting
Premium
Company Announcements
Shareholders Approve Directors, Auditors at 2026 Meeting
3M ago
Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―